LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

10.79 0.28

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.64

Massimo

10.86

Metriche Chiave

By Trading Economics

Entrata

212M

25M

Vendite

4.5M

9M

EPS

-0.199

Margine di Profitto

280.018

Dipendenti

908

EBITDA

-52M

-274M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+68.7% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

7.8B

Apertura precedente

10.51

Chiusura precedente

10.79

Notizie sul Sentiment di mercato

By Acuity

50%

50%

173 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 mag 2025, 22:52 UTC

Utili
I principali Market Mover

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mag 2025, 20:37 UTC

Notizie principali
Utili

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mag 2025, 00:00 UTC

Discorsi di Mercato

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mag 2025, 23:14 UTC

Notizie principali

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mag 2025, 22:46 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 21:58 UTC

Utili

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mag 2025, 21:24 UTC

Utili

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mag 2025, 20:56 UTC

Discorsi di Mercato

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mag 2025, 20:54 UTC

Discorsi di Mercato
Utili

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mag 2025, 20:54 UTC

Utili

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mag 2025, 20:51 UTC

Utili

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 mag 2025, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mag 2025, 20:50 UTC

Utili

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mag 2025, 20:26 UTC

Notizie principali

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mag 2025, 20:25 UTC

Utili

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

68.7% in crescita

Previsioni per 12 mesi

Media 18 USD  68.7%

Alto 18 USD

Basso 18 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

11 / 11.18Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

173 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.